Roche unloads some rights to drug hopeful after asthma trial disappointment


Roche is offloading some rights to what was once one of its top drug prospects, lebrikizumab, for payments that could total more than $1 billion after the medicine produced only lackluster results in an asthma study during 2016.
Source link